```html

Herpes Simplex Virus Type 1 (HSV‑1): A Complete Patient‑Friendly Guide

Overview

Herpes simplex virus type 1 (HSV‑1) is a common DNA virus that primarily causes oral (“cold‑sore”) lesions, but it can also affect the eyes, skin, and genital area. The virus is highly contagious and can be transmitted through direct contact with infected secretions (saliva, tears, genital secretions) or contaminated surfaces.

Who it affects: HSV‑1 can infect anyone, regardless of age, gender, or ethnicity. Children acquire it through non‑sexual contact (e.g., sharing utensils, kissing), while adolescents and adults often acquire it through oral‑genital contact.

Prevalence: According to the World Health Organization (WHO), about 3.7 billion people (≈50 % of the global population) are infected with HSV‑1. In the United States, the CDC estimates that roughly 47 % of people aged 14‑49 have HSV‑1 antibodies, indicating prior exposure.

Symptoms

Many people with HSV‑1 never notice symptoms because the infection can be subclinical. When symptoms do appear, they typically follow a predictable pattern.

Primary (initial) infection

• Fever, malaise, headache: General “flu‑like” feeling that may last 3‑7 days.
• Enlarged lymph nodes (especially submandibular or cervical).
• Oral lesions: Small, painful vesicles on the lips, gums, tongue, or palate that rupture to form shallow ulcers.
• Gingivostomatitis: Swollen, red gums with ulceration; common in children.
• Genital lesions (if acquired through oral‑genital contact): Similar vesicles on the vulva, penis, or perianal area.
• Eye involvement (herpes keratitis): Redness, tearing, photophobia, and blurred vision.

Recurrent (reactivation) infections

• Prodrome: Tingling, itching, or burning sensation 12‑48 hours before lesions appear.
• Cold sores (fever blisters): Clusters of 2‑5 fluid‑filled vesicles on the vermilion border of the lip; they crust over in 5‑10 days.
• Genital recurrence: Similar prodrome and lesions in the genital area, often milder than the primary episode.
• Herpes keratitis recurrence: Pain, photophobia, and corneal ulceration; may lead to scarring.

Some individuals experience atypical lesions such as perianal or shoulder‑blade (herpes gladiatorum) eruptions, especially athletes involved in close‑contact sports.

Causes and Risk Factors

What causes HSV‑1 infection?

HSV‑1 is transmitted via direct contact with infected secretions. The virus enters through mucous membranes or micro‑abrasions in the skin. Once inside, it travels to sensory nerve ganglia (commonly the trigeminal ganglion for oral infection) where it establishes latency. Reactivation can occur months or years later.

Risk factors for acquisition and reactivation

• Close personal contact: Kissing, sharing utensils, lip balm, or razors.
• Oral‑genital sexual activity: Increases genital HSV‑1 infection risk.
• Immunosuppression: HIV infection, organ transplantation, chemotherapy, or chronic steroid use.
• Stress and fatigue: Physical or emotional stress can trigger reactivation.
• Sunlight/UV exposure: UV light damages mucosal cells and can precipitate cold‑sore outbreaks.
• Trauma to the affected area: Dental work, facial injuries, or laser treatments.
• Hormonal changes: Menstruation or pregnancy may increase recurrence frequency.

Diagnosis

Accurate diagnosis guides treatment and counseling.

Clinical evaluation

• Visual inspection of lesions (characteristic vesicles on an erythematous base).
• History taking – prior episodes, sexual practices, recent stressors, or immunosuppression.

Laboratory tests

• Polymerase chain reaction (PCR) from lesion swab – gold standard, >95 % sensitivity.
• Viral culture – less commonly used; slower turnaround.
• Direct fluorescent antibody (DFA) test – rapid but less sensitive than PCR.
• Serologic testing (IgG/IgM antibodies) – useful when lesions are absent; IgG indicates past exposure, IgM may suggest recent infection.

For ocular involvement, a slit‑lamp examination by an ophthalmologist is essential, and corneal scraping for PCR may be performed.

Treatment Options

While there is no cure for HSV‑1, antiviral therapy shortens outbreaks, reduces severity, and lowers transmission risk.

Medications

• Acyclovir (Zovirax) – 200‑400 mg orally 5 times daily for 5‑10 days (primary infection) or 800 mg 5 times daily for recurrent lesions.
• Valacyclovir (Valtrex) – 1 g once daily for 5 days (primary) or 2 g twice daily for 1 day (recurrent “on‑demand”).
• Famciclovir (Famvir) – 250 mg three times daily for 5 days (primary) or 1 g single dose for recurrent.
• Suppressive therapy: For ≥4 outbreaks per year, daily valganciclovir (500 mg) or acyclovir (400 mg twice daily) reduces recurrence by ~70 % (source: CDC).

Topical options

• Topical acyclovir 5 % cream – modest benefit; best used within 48 hours of prodrome.
• Penciclovir 1 % cream (Denavir) – comparable efficacy to topical acyclovir.

Procedural interventions

• Laser or cryotherapy – sometimes employed for recurrent keratitis resistant to medication.
• Intravenous antivirals – Acyclovir 5‑10 mg/kg every 8 hours for severe disseminated infection or encephalitis (hospital setting).

Lifestyle & supportive care

• Apply cool compresses to reduce pain.
• Stay hydrated and use analgesics (ibuprofen or acetaminophen) for fever/malaise.
• Avoid acidic or salty foods that irritate oral ulcers.

Living with Herpes Simplex Virus Infection (HSV‑1)

Managing HSV‑1 is a blend of medical treatment, self‑care, and emotional support.

• Recognize prodrome signs and start on‑demand antivirals promptly to curb lesion development.
• Maintain good oral hygiene – gentle brushing, alcohol‑free mouthwash.
• Protect your eyes – wear sunglasses on sunny days; seek urgent care for any redness or vision changes.
• Stress‑reduction techniques – regular exercise, meditation, adequate sleep.
• Stay informed – keep a diary of triggers (sun exposure, menstrual cycle) to anticipate outbreaks.
• Communicate with partners – disclose infection status, use barriers (condoms, dental dams) during outbreaks, consider suppressive therapy to lower transmission.
• Seek counseling if needed – feelings of shame or anxiety are common; support groups and mental‑health professionals can help.

Prevention

Although HSV‑1 is widespread, several practical steps can markedly reduce acquisition and transmission.

• Avoid sharing personal items that contact saliva (lip balm, utensils, toothbrushes).
• Refrain from kissing or oral contact when you have an active sore.
• Use condoms or dental dams during oral‑genital contact, even if lesions are not visible.
• Apply broad‑spectrum sunscreen or lip balm with SPF 15+ on lips before prolonged sun exposure.
• For individuals with frequent outbreaks, discuss daily suppressive antiviral therapy with a clinician.
• Pregnant women with genital HSV‑1 should inform obstetric providers; antiviral prophylaxis in the third trimester can lower neonatal transmission risk.

Complications

Most HSV‑1 infections are self‑limited, but complications can occur, especially in vulnerable populations.

• Herpes keratitis – leading cause of infectious blindness in the United States; scarring can cause permanent vision loss (Mayo Clinic).
• Eczema herpeticum – disseminated skin infection in patients with atopic dermatitis; may progress to sepsis.
• Neonatal herpes – rare but severe when a newborn acquires HSV‑1 during delivery; presents with skin, eye, mouth lesions or systemic disease.
• Encephalitis – HSV‑1 is the most common cause of sporadic viral encephalitis; presents with fever, headache, seizures, and altered mental status.
• Psychosocial impact – anxiety, depression, and relationship strain related to stigma.

When to Seek Emergency Care

For all other concerns—frequent recurrences, persistent sores, or questions about suppressive therapy—schedule an appointment with your primary care provider or a dermatologist.

---

Sources: World Health Organization (2023); Centers for Disease Control and Prevention (2022); Mayo Clinic; Cleveland Clinic; National Institutes of Health – MedlinePlus; peer‑reviewed articles in JAMA Dermatology and Ophthalmology (2021‑2024).

```